Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

2h-chromene derivatives as analgesic agents

Active Publication Date: 2017-06-08
OBSHESTVO S OGRANICHENNOI OTVETSVENNOSTJU LEOFORS
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention is about developing new low toxic drugs that have analgesic activity. The invention is achieved by using compounds of general formula 1, which can be synthesized using different raw materials and methods. The compounds have been tested in animal models and found to have potent analgesic activity, making them effective drugs for treating pain. The compounds can be administered in different doses and are even more effective than the reference drug sodium diclofenac. The invention provides a new tool for developing new drugs with improved pain-relieving properties.

Problems solved by technology

The disadvantage of acetylsalicylic acid is low activity and gastrointestinal toxicity; metamizole may induce hematopoiesis disorders, up to agranulocytosis.
The disadvantages of sodium diclofenac are adverse gastrointestinal effects (gastrointestinal toxicity).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 2h-chromene derivatives as analgesic agents
  • 2h-chromene derivatives as analgesic agents
  • 2h-chromene derivatives as analgesic agents

Examples

Experimental program
Comparison scheme
Effect test

example 1

of 4,7-dimethyl-2-(thiophene-2-yl)octahydro-2H-chromene-4-ol 1a

[0024]

[0025]A solution of 0.29 g thiophene-2-carbaldehyde in 3 ml CH2Cl2 was added to a suspension of 1.3 g of K10 clay in 5 ml CH2Cl2, then a solution of 0.400 g isopulegol 2 in 3 ml CH2Cl2 was added. The solvent was evaporated and the reaction mixture was kept at room temperature during 60 min. Then 10 ml of EtOAc was added, the catalyst was filtered and the solvent was evaporated. The resulting mixture was separated at a column with 13 g silica gel (eluent: solution of 0 to 100% ethyl acetate in hexane). 0.543 g (yield 78%) of compound 1a was obtained. NMR 1H spectrum of compound 1a corresponds to the spectrum, published in the literature [4].

example 2

of 4,7-dimethyl-2-(3-methylthiophene-2-yl)octahydro-2H-chromene-4-ol 1b

[0026]

[0027]Similar to Example 1, interaction of 0.300 g isopulegol 2 with 0.25 g 3-methylthiophene-2-carbaldehyde in the presence of 1.1 g K10 clay during 120 min resulted in 0.381 g (yield 70%) of compound 1b.

[0028]Spectrum NMR 1H (CDCl3): 0.88-0.97 (m, 1H, Ha-8); 0.92 (d, J (16, 9a)=6.6 Hz, 3H, H-16); 1.03 (dddd, J (7a, 7e)=J (7a, 8a)=12.8 Hz, J (7a, 6a)=12.1 Hz, J (7a, 8e)=3.3 Hz, 1H, Ha-7); 1.11 (ddd, J (10a, 10e)=J (10a, 9a)=12.2 Hz, J (10a, 1a)=10.8 Hz, 1H, Ha-10); 1.28 (d, J (15, 4a)=0.7 Hz, 3H, H-15); 1.31 (ddd, J (6a, 7a)=12.1 Hz, J (6a, 1a)=10.2 Hz, J (6a, 7e)=3.3 Hz, 1H, Ha-6); 1.40-1.53 (m, 2H, Ha-9, OH); 1.72 (ddddd, J (8e, 8a)=12.9 Hz, J (8e, 7a)=J (8e, 9a)=J (8e, 7e)=3.3 Hz, J (8e, 10e)=2.0 Hz, 1H, He-8); 1.85 (ddq, J (4a, 4e)=12.7 Hz, J (4a, 3a)=11.7 Hz, J (4a, 15)=0.7 Hz, 1H, Ha-4); 1.91-1.97 (m, 1H, He-7); 1.95 (dd, J (4e, 4a)=12.7 Hz, J (4e, 3a)=2.4 Hz, 1H, He-4); 1.99 (dm, J (10e, 10a)=12.2 H...

example 3

of 4,7-dimethyl-2-(5-methylthiophene-2-yl)octahydro-2H-chromene-4-ol 1c

[0029]

[0030]Similar to Example 1, interaction of 0.300 g isopulegol 2 with 0.25 g 5-methylthiophene-2-carbaldehyde in the presence of 1.1 g K10 clay during 120 min resulted in 0.386 g (yield 71%) of compound 1c.

[0031]Spectrum NMR 1H (CDCl3): 0.87-0.96 (m, 1H, Ha-8); 0.92 (d, J (16, 9a)=6.6 Hz, 3H, H-16); 1.02 (dddd, J (7a, 7e)=J (7a, 8a)=12.8 Hz, J (7a, 6a)=12.2 Hz, J (7a, 8e)=3.3 Hz, 1H, Ha-7); 1.09 (ddd, J (10a, 10e)=J (10a, 9a)=12.3 Hz, J (10a, 1a)=10.8 Hz, 1H, Ha-10); 1.25 (d, J (15, 4a)=0.8 Hz, 3H, H-15); 1.28 (ddd, J (6a, 7a)=12.2 Hz, J (6a, 1a)=10.2 Hz, J (6a, 7e)=3.3 Hz, 1H, Ha-6); 1.39-1.52 (m, 2H, Ha-9, OH); 1.72 (ddddd, J (8e, 8a)=12.8 Hz, J (8e, 7a)=J (8e, 9a)=J (8e, 7e)=3.3 Hz, J (8e, 10e)=2.0 Hz, 1H, He-8); 1.86 (ddq, J (4a, 4e)=12.7 Hz, J (4a, 3a)=11.7 Hz, J (4a, 15)=0.8 Hz, 1H, Ha-4); 1.93 (dddd, J (7e, 7a)=12.8 Hz, J (7e, 6a)=J (7e, 8a)=J (7e, 8e)=3.3 Hz, 1H, He-7); 1.99 (dm, J (10e, 10a)=12.3 Hz...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Toxicityaaaaaaaaaa
Login to View More

Abstract

The invention relates to the use of the compound of general formula 1 or its spatial isomersas an analgesic drug. The compounds have high activity, low toxicity, may be used in medicine.

Description

FIELD OF THE INVENTION[0001]The invention relates to the field of medicine, specifically, to drugs having analgesic effect.BACKGROUND OF THE INVENTION[0002]Analgesic drugs are known, that are nonnarcotic analgesics by their mechanism of action, such as acetylsalicylic acid, metamizole and others [1]. Data on activity in acetic acid induced writhing test (ED50) and acute toxicity (LD50) of the known drugs are presented in [2] and in Table 1.TABLE 1Toxicity and analgesic action of the known drugs [2].DrugED50, mg / kgLD50, mg / kgAcetylsalicylic acid1551600Metamizole553300Sodium diclofenac5370[0003]The disadvantage of acetylsalicylic acid is low activity and gastrointestinal toxicity; metamizole may induce hematopoiesis disorders, up to agranulocytosis.[0004]Diclofenac sodium [3] was chosen as a prototype.[0005]The disadvantages of sodium diclofenac are adverse gastrointestinal effects (gastrointestinal toxicity).DESCRIPTION OF THE INVENTION[0006]The goal of the invention is the developme...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/381
CPCA61K31/381A61K31/353A61P29/00
Inventor KHAID, EKATERINA VLADIMIROVNAPAVLOVA, ALLA VIKTOROVNAMIKHAL'CHENKO, OKSANA STANISLAVOVNAKORCHAGINA, DINA VLADIMIROVNATOLSTIKOVA, TATIANA GENRIHOVNAVOLCHO, KONSTANTIN PETROVICHKHAZANOV, VENIAMIN ABRAMOVICHSALAKHUTDINOV, NARIMAN FARIDOVICH
Owner OBSHESTVO S OGRANICHENNOI OTVETSVENNOSTJU LEOFORS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com